Article Information
History
- July 29, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Guillaume Grenet, MD1,*,
- Samia Mekhaldi, PharmD2,
- Sabine Mainbourg, MD5,
- Marine Auffret, PharmD1,
- Catherine Cornu, MD2,3,
- Prof Jean-Luc Cracowski, MD4,
- Prof François Gueyffier, MD2,
- Prof Jean-Christophe Lega, MD5 and
- Prof Michel Cucherat, MD1,2
- 1Hospices Civils de Lyon, Pôle Santé Publique, Service hospitalo-universitaire de pharmacotoxicologie, Lyon, France
- 2Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR 5558, F-69622 Villeurbanne, France
- 3CIC1407 INSERM, Hospices Civils de Lyon, Lyon, France
- 4Univ. Grenoble Alpes, INSERM, HP2, and centre régional de pharmacovigilance de Grenoble, F-38000 Grenoble, France
- 5Hospices Civils de Lyon, Hôpital Lyon Sud, Service de Médecine Interne et Vasculaire, Lyon, France
- ↵*Correspondance to: Dr Guillaume Grenet, Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, LYON, France, guillaume.grenet{at}chu-lyon.fr
Posted July 29, 2020.
DPP4 inhibitors and respiratory infection, a systematic review and meta-analysis of the CardioVascular Outcomes Trials conducted before the pandemic and implications for the management of diabetes during COVID-19
